Astellas bets on Vir cancer drug, and other licensing deals Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

#pharmalicensingdeals #pharmaceuticalassets #VirBiotech #Vir #HarbourBioMed #UnnaturalProducts #Genhouse #CSL #Astellas #SolsticeOncology #antiCTLA4antibody #Novartis #UnnaturalProducts #macrocyclicpeptidedrugs #GileadSciences #syntheticlethality #GenhouseBio #Arcellx #EliLilly
zurl.co/HOdjt

Our latest round-up of #pharmalicensing deals features assets from #VirBiotech, #HarbourBioMed, #UnnaturalProducts, #Genhouse, and #CSL.

pharmaphorum.com/news/astella...

#VirBiotech intent on burning through $1B in cash over next 2 years frankly is #obscene.

Any reasonable grounded Co w/ that type of cash would extend the cash runway into 2028, if not 2029...just to be sure.